Clinical trial disappointments and technical sell signals pressure VRTX, down 15% over six months. Get Pro-Level Earnings Insights Before the Market Moves This occurs when the 50-day moving ...
Vertex Pharmaceuticals (VRTX) shares soared 5.3% in the last trading session to close at $461.68. The move was backed by solid volume with far more shares changing hands than in a normal session.
Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback